Triptorelin
Mechanism :
Triptorelin is an agonist analog of gonadotropin releasing hormone (GnRH) and causes suppression of ovarian and testicular steroidogenesis.
Indication :
- Central precocious puberty
Contraindications :
Known hypersensitivity to triptorelin or any component of the formulation, other GnRH agonists or GnRH; pregnancy.
Dosing :
Children ≥2 years:
22.5 mg IM once every 24 weeks. Discontinue therapy at appropriate age of onset of puberty.
Adverse Effect :
Hot flushes, skeletal pain, injection site pain and redness, nasopharyngitis, headache, impotence, vaginal bleeding.
Interaction :
Amiodarone, Anagrelide, Dofetilide: Triptorelin increases toxicity by prolonging QTc interval. Contraindicated. Increases risk of torsades de pointes.
Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | Dose as in normal renal function |
| 10-20 | Dose as in normal renal function, but monitor carefully |
| <10 | Dose as in normal renal function, but monitor carefully |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully |
| HD | Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully |
| HDF/High flux | Unknown dialysability. Dose as in normal renal function, but monitor carefully |
| CAV/VVHD | Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully |
Hepatic Dose :
Dose adjustment guidelines are not available. Use cautiously. Dose reduction may be needed as impaired hepatic metabolism increases systemic levels of drug due to reduced clearance and increases the risk of adverse effects.